Effect of Adductor-Canal-Blockade on High Pain Responders the 1. or 2. Postoperative Day After Total Knee Arthroplasty
Overview
- Phase
- Phase 4
- Intervention
- Ropivacaine
- Conditions
- Pain After Total Knee Arthroplasty
- Sponsor
- University Hospital, Gentofte, Copenhagen
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Difference in VAS between ACB and placebo during active 45 degrees knee flexion
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to determine whether Adductor-Canal-Blockade (ACB) is superior to placebo when it comes to analgetic efficacy in high pain responders after Total Knee Arthroplasty (TKA). High pain responders are defined as patients reporting VAS > 60 during knee flexion the 1. or 2. day after surgery.
Detailed Description
The patients will be included the 1. or 2. day after surgery. All TKA patients will be screened. Those reporting VAS \> 60 during active 45 degrees knee flexion will be asked to participate. Included patients will receive 2xACB (singleshot) first placebo (30ml saline) and then ropivacaine (30ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.
Investigators
Ulrik Grevstad
Consultant
University Hospital, Gentofte, Copenhagen
Eligibility Criteria
Inclusion Criteria
- •TKA within 48 hours and VAS\>60 during active 45 degrees knee flexion despite conventional pain medication.
- •Informed consent
- •BMI 18-40
Exclusion Criteria
- •Unable to communicate in Danish
- •Allergic reactions toward drugs used in the
- •Abuse of alcohol/drugs
- •Unable to cooperate
Arms & Interventions
Arm RP
first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
Intervention: Ropivacaine
Arm RP
first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
Intervention: Saline
Arm PR
first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
Intervention: Ropivacaine
Arm PR
first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
Intervention: Saline
Outcomes
Primary Outcomes
Difference in VAS between ACB and placebo during active 45 degrees knee flexion
Time Frame: 45 minutes
Secondary Outcomes
- Difference in mean VAS between the groups at rest(15, 30, 60, 75 and 90 minutes)
- Difference in mean VAS between the groups during active knee flexion(15, 30, 60, 75 and 90 minutes)